SEC Company Response from Cardiff Oncology, Inc. (CRDF) (CIK 0001213037) (CRDF) — May 29, 2012
Cardiff Oncology, Inc. (CRDF) (CIK 0001213037)
Date: May 29, 2012 · CIK: 0001213037 · Accession: 0001104659-12-040234
AI Filing Summary & Sentiment
File numbers found in text: 333-180810
Letter
Trovagene, Inc.
11055 Flintkote Avenue
San Diego, CA 92121
May 25, 2012
VIA EDGAR
United States Securities
and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549
Attention: Karen Ubell
Re: Trovagene, Inc.
Registration Statement on Form S-1
File No. 333-180810
Ladies and Gentlemen:
Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended (the “Act”), Trovagene, Inc. (the “Company”) respectfully requests that the effective date of the registration statement referred to above be accelerated so that it will become effective at 5 p.m., Washington D.C., on May 29, 2012, or as soon thereafter as possible. The Company acknowledges that: 1) should the Commission or the staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing; 2) the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and 3) the Company may not assert the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
TROVAGENE, INC.
By:
/s/ Antonius Schuh
Name: Antonius Schuh
Title: Chief Executive Officer
Show Raw Text
CORRESP
1
filename1.htm
Trovagene, Inc.
11055 Flintkote Avenue
San Diego, CA 92121
May 25, 2012
VIA EDGAR
United States Securities
and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549
Attention: Karen Ubell
Re: Trovagene, Inc.
Registration Statement on Form S-1
File No. 333-180810
Ladies and Gentlemen:
Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended (the “Act”), Trovagene, Inc. (the “Company”) respectfully requests that the effective date of the registration statement referred to above be accelerated so that it will become effective at 5 p.m., Washington D.C., on May 29, 2012, or as soon thereafter as possible. The Company acknowledges that: 1) should the Commission or the staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing; 2) the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and 3) the Company may not assert the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
TROVAGENE, INC.
By:
/s/ Antonius Schuh
Name: Antonius Schuh
Title: Chief Executive Officer